Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2020. The company is hosting a conference call at 4:30 p.m. EST to discuss results.

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results

Pasadena. CA | Posted on November 23rd, 2020

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 8492751.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 8492751.

Selected Recent Events

Earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, now called olpasiran, in a Phase 2 clinical study
Hosted a key opinion leader webinar on ARO-ENaC, the company’s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis
Initiated a Phase 1b study of ARO-HIF2, the company’s first tumor targeted investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma
Presented new clinical data from Phase 1/2 studies of both wholly owned cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, at multiple medical meetings, including the European Society of Cardiology and the American Heart Association meetings, and subsequently hosted key opinion leader webinars to discuss the data and plans for future development of the product candidates
Presented new clinical data at The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) on ARO-AAT, Arrowhead’s candidate against liver disease associated with alpha-1 antitrypsin deficiency, showing that ARO-AAT strongly reduced the production of mutant Z-AAT protein and led to improvements in multiple biomarkers of alpha-1 liver disease
Signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT, which includes $300 million upfront, $740 million in potential milestone payments, a 50/50 profit sharing agreement in the U.S., and 20-25% royalty on sales outside the U.S.
Selected Fiscal Year 2020 Financial Results

ARROWHEAD PHARMACEUTICALS, INC.

CONSOLIDATED CONDENSED FINANCIAL INFORMATION

















Year Ended September 30,



OPERATING SUMMARY

2020



2019

















REVENUE

$

87,992,066





$

168,795,577



OPERATING EXPENSES













Research and development



128,874,979







81,048,686



General and administrative expenses



52,275,890







26,556,257



TOTAL OPERATING EXPENSES



181,150,869







107,604,943



OPERATING INCOME (LOSS)



(93,158,803

)





61,190,634



OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES



8,605,577







6,784,215



NET INCOME (LOSS)

$

(84,553,226

)



$

67,974,849

















NET INCOME (LOSS) PER SHARE (DILUTED)

$

(0.84

)



$

0.69



WEIGHTED AVERAGE SHARES OUTSTANDING (DILUTED)



100,722,224







98,607,815

















FINANCIAL POSITION SUMMARY

September 30,



September 30,





2020



2019



CASH AND CASH EQUIVALENTS

$

143,582,667





$

221,804,128



SHORT-TERM INVESTMENTS AND MARKETABLE SECURITIES



171,909,470







36,899,894



LONG-TERM INVESTMENTS



137,486,883







44,175,993



TOTAL CASH RESOURCES (CASH AND INVESTMENTS)



452,979,020







302,880,015



OTHER ASSETS



69,524,723







46,965,422



TOTAL ASSETS



522,503,743







349,845,437



TOTAL CURRENT DEFERRED REVENUE



19,291,075







77,769,629



TOTAL LONG TERM DEFERRED REVENUE



-







5,035,142



OTHER LIABILITIES



41,433,536







23,004,414



TOTAL LIABILITIES



60,724,611







105,809,185



TOTAL STOCKHOLDERS' EQUITY



461,779,132







244,036,252



TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$

522,503,743





$

349,845,437

















SHARES OUTSTANDING



102,376,303







95,506,271



####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New technique builds super-hard metals from nanoparticles January 22nd, 2021

Squeezing a rock-star material could make it stable enough for solar cells: A promising lead halide perovskite is great at converting sunlight to electricity, but it breaks down at room temperature; now scientists have discovered how to stabilize it with pressure from a diamond a January 22nd, 2021

Researchers develop new graphene nanochannel water filters January 22nd, 2021

Pioneering new technique could revolutionise super-resolution imaging systems January 22nd, 2021

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results January 20th, 2021

Chemists invent shape-shifting nanomaterial with biomedical potential It converts from sheets to tubes and back in a controllable fashion January 13th, 2021

Nanocrystals that eradicate bacteria biofilm January 8th, 2021

Detecting COVID-19 antibodies in 10-12 seconds January 8th, 2021

Announcements

New technique builds super-hard metals from nanoparticles January 22nd, 2021

Squeezing a rock-star material could make it stable enough for solar cells: A promising lead halide perovskite is great at converting sunlight to electricity, but it breaks down at room temperature; now scientists have discovered how to stabilize it with pressure from a diamond a January 22nd, 2021

Researchers develop new graphene nanochannel water filters January 22nd, 2021

Pioneering new technique could revolutionise super-resolution imaging systems January 22nd, 2021

Financial Reports

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results January 20th, 2021

180 Degree Capital Corp. Reports +7.4% Growth and $2.90 Per Share NAV as of September 30, 2020, and Developments From Q4 2020 November 19th, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results November 3rd, 2020

180 Degree Capital Corp. to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020 and to Host a Conference Call on Tuesday, August 11, 2020 August 7th, 2020

Events/Classes

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results January 20th, 2021

SEMICON Japan 2020 Virtual Set to Open with Sustainable Industry Growth, Smart Technology in the Spotlight December 8th, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences December 2nd, 2020

Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020 November 13th, 2020

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results January 20th, 2021

Chemists invent shape-shifting nanomaterial with biomedical potential It converts from sheets to tubes and back in a controllable fashion January 13th, 2021

Nanocrystals that eradicate bacteria biofilm January 8th, 2021

Detecting COVID-19 antibodies in 10-12 seconds January 8th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project